Race Oncology gains ethics approval for HARNESS-1 lung cancer trial

Race Oncology (ASX:RAC) has received human ethics approval from St Vincent’s Hospital Melbourne HREC to commence its HARNESS-1 Phase 1a/b trial for RC220 in EGFR-mutated non-small cell lung cancer (NSCLC).

The trial, led by Monash Health and principal investigator Dr Surein Arulananda, will evaluate RC220 in combination with AstraZeneca’s Tagrisso (osimertinib) to address drug resistance in NSCLC patients. Phase 1a will focus on dose escalation and safety, while Phase 1b will explore early efficacy signals, including progression-free survival and ctDNA changes. RC220, a G-quadruplex binder, aims to prolong osimertinib’s effectiveness by targeting resistance pathways, addressing a critical unmet need in lung cancer treatment. Patient recruitment is expected to begin between late Q4 2025 and early Q1 2026.

Read the full article: https://stockhead.com.au/health/race-oncology-gains-ethics-approval-for-harness-1-lung-cancer-trial/